Fidia has several decades of unparalleled experience developing innovative solutions in key therapeutic areas where hyaluronic acid properties can be effectively, efficiently, and rationally exploited, such as joint care and wound healing.

In the sector of intra-articular joint therapy, Fidia plays a leading role in Europe and is a top player in the United States with its FDA-approved, hyaluronic acid-based products for the treatment of osteoarthritis, thus confirming the high quality standards, i.e. extreme purity of raw material and safety of the finished products, of Fidia’s production capacities.

The company is also expanding its portfolio, including products and line extensions in women’s health and aesthetic medicine, and continues to be strongly focused on neuroscience and ophthalmology, with important R&D projects at various stages of development.

More recently, based on its strong experience in the clinical applications of hyaluronic acid and in the field of tissue regeneration, Fidia took up the challenge of entering the field of autologous biological therapy.